US 11,690,586 B2
Systems, methods, and devices for medical image analysis, diagnosis, risk stratification, decision making and/or disease tracking
James K. Min, Denver, CO (US); James P. Earls, Fairfax Station, VA (US); Hugo Miguel Rodrigues Marques, Lisbon (PT); and Ben Hootnick, New York, NY (US)
Assigned to CLEERLY, INC., Denver, CO (US)
Filed by CLEERLY, INC., Denver, CO (US)
Filed on Dec. 30, 2022, as Appl. No. 18/149,021.
Application 18/149,021 is a continuation of application No. 17/662,734, filed on May 10, 2022.
Application 17/662,734 is a continuation of application No. 17/367,549, filed on Jul. 5, 2021, granted, now 11,367,190, issued on Jun. 21, 2022.
Application 17/367,549 is a continuation of application No. 17/350,836, filed on Jun. 17, 2021.
Application 17/350,836 is a continuation in part of application No. 17/213,966, filed on Mar. 26, 2021, granted, now 11,094,060, issued on Aug. 17, 2021.
Application 17/213,966 is a continuation of application No. 17/142,120, filed on Jan. 5, 2021, granted, now 11,501,436, issued on Nov. 15, 2022.
Claims priority of provisional application 63/201,142, filed on Apr. 14, 2021.
Claims priority of provisional application 63/142,873, filed on Jan. 28, 2021.
Claims priority of provisional application 63/089,790, filed on Oct. 9, 2020.
Claims priority of provisional application 63/077,058, filed on Sep. 11, 2020.
Claims priority of provisional application 63/077,044, filed on Sep. 11, 2020.
Claims priority of provisional application 63/041,252, filed on Jun. 19, 2020.
Claims priority of provisional application 62/958,032, filed on Jan. 7, 2020.
Prior Publication US 2023/0148981 A1, May 18, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. G06K 9/00 (2022.01); A61B 6/00 (2006.01); A61B 8/14 (2006.01); A61B 6/03 (2006.01); A61B 5/00 (2006.01); G06T 7/00 (2017.01); A61B 8/12 (2006.01); A61B 5/055 (2006.01); A61K 49/04 (2006.01); A61B 5/02 (2006.01); G06F 18/10 (2023.01); G06V 10/74 (2022.01); G06V 10/764 (2022.01); G06V 10/20 (2022.01); G06V 10/24 (2022.01); G06V 40/14 (2022.01)
CPC A61B 6/481 (2013.01) [A61B 5/0066 (2013.01); A61B 5/0075 (2013.01); A61B 5/02007 (2013.01); A61B 5/055 (2013.01); A61B 5/7267 (2013.01); A61B 5/742 (2013.01); A61B 5/7475 (2013.01); A61B 6/032 (2013.01); A61B 6/037 (2013.01); A61B 6/504 (2013.01); A61B 6/5205 (2013.01); A61B 6/5217 (2013.01); A61B 8/12 (2013.01); A61B 8/14 (2013.01); A61K 49/04 (2013.01); G06F 18/10 (2023.01); G06T 7/0012 (2013.01); G06V 10/20 (2022.01); G06V 10/245 (2022.01); G06V 10/761 (2022.01); G06V 10/764 (2022.01); G06V 40/14 (2022.01); G06T 2207/10081 (2013.01); G06T 2207/10088 (2013.01); G06T 2207/10101 (2013.01); G06T 2207/10132 (2013.01); G06T 2207/20081 (2013.01); G06T 2207/30048 (2013.01); G06T 2207/30101 (2013.01); G06V 10/247 (2022.01)] 30 Claims
OG exemplary drawing
 
1. A computer-implemented method of determining continued treatment for a subject with atherosclerotic cardiovascular disease (ASCVD) risk based on coronary CT angiography (CCTA) analysis using one or more quantitative imaging algorithms, the method comprising:
assessing, by a computer system, baseline CCTA analysis results of the subject, wherein the baseline CCTA analysis results are generated by applying one or more quantitative imaging algorithms to a first medical image of the subject obtained at a first point in time, the baseline CCTA analysis results comprising one or more atherosclerosis parameters or perivascular tissue parameters, the one or more atherosclerosis parameters comprising one or more of presence, locality, extent, severity, or type of atherosclerosis;
accessing, by the computer system, a second medical image of the subject obtained at a second point in time after applying an initial treatment to the subject, the initial treatment determined based at least in part on the baseline CCTA analysis results of the subject, the initial treatment for the subject comprising one or more of medication, lifestyle, or interventional therapy;
assessing, by the computer system, subject response to the initial treatment by:
applying one or more quantitative imaging algorithms to the second medical image of the subject to generate subsequent CCTA analysis results, the subsequent CCTA analysis results comprising the one or more atherosclerosis parameters or perivascular tissue parameters;
determining one or more changes between the baseline CCTA analysis results and the subsequent CCTA analysis results;
generating an ASCVD risk of the subject at the second point in time based at least in part on the subsequent CCTA analysis results and the determined one or more changes between the baseline CCTA analysis results and the subsequent CCTA analysis results; and
assessing subject response to the initial treatment based at least in part on the generated ASCVD risk of the subject at the second point in time, wherein the subject response is assessed based on one or more of progression, stabilization, or regression of ASCVD risk; and
causing, by the computer system, display of the subject response to the initial treatment, wherein the displayed subject response to the initial treatment is configured to be used to determine a continued proposed treatment for the subject, the continued proposed treatment comprising a higher tiered approach than the initial treatment when the assessed subject response comprises progression of ASCVD, wherein the continued personalized proposed treatment comprises one or more of medication, lifestyle, or interventional therapy,
wherein the computer system comprises a computer processor and an electronic storage medium.